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Tubulointerstitial damageDeterioration of diabetic nephropathy (DN) is largely determined by the degree of tubulointerstitial changes
rather than the extent of histological changes in the glomeruli. Therefore, a tubular marker that accurately
reﬂects tubulointerstitial damage may be an excellent biomarker for early detection or prediction of DN.
Liver-type fatty-acid binding protein (L-FABP) is a 14 kDa small molecule that is expressed in the cytoplasm
of human proximal tubules. In vivo experimental studies revealed that renal L-FABP gene expression was
up-regulated by various stresses that cause tubulointerstitial damage, such as massive proteinuria, hypergly-
cemia, hypertension, ischemia and toxins, and that urinary excretion of L-FABP was increased. Recent clinical
studies of patients with type 1 or type 2 diabetes demonstrated that urinary excretion of L-FABP derived from
proximal tubules is a suitable biomarker for predicting and monitoring deterioration of renal function in DN.
Moreover, therapeutic interventions with renoprotective effects reduced urinary L-FABP concentrations.
Therefore, urinary L-FABP measured using the Human L-FABP ELISA Kit developed by CMIC Co., Ltd.
(Tokyo, Japan) was conﬁrmed as a newly established tubular biomarker by the Ministry of Health, Labour
andWelfare in Japan in 2010. This review article summarizes the clinical signiﬁcance of urinary L-FABP in DN.
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Diabetic nephropathy (DN) is the leading cause of chronic kidney
disease (CKD), which ultimately progresses to end-stage renal failure
and increases the risk of cardiovascular disease. Therefore, early diag-
nostic markers for predicting and monitoring the progression of DN
are needed to enable the timely administration of the most appropri-
ate protective treatments.
Tubulointerstitial injury has been suggested to have an important
impact on the progression of DN [1]. Liver-type fatty-acid binding. 
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kidney and participates in fatty acid metabolism [2]. Results of animal
studies of kidney disease showed that human L-FABP gene expression
in the kidney was up-regulated and that urinary excretion of human
L-FABP was increased by stress (e.g., urinary protein overload [3], tu-
bular ischemia [4], tubular stretch [5], hyperglycemia [6], toxins [7,8]
and hypertension [9] that causes tubulointerstitial damage. In a clin-
ical study of patients with non-diabetic CKD, urinary excretion of
L-FABP was found to correlate with the severity of tubulointerstitial
damage [3] and with the rate of CKD progression [10]. Urinary
L-FABP thus offers potential as a clinical marker to screen for kidney
dysfunction and thereby to identify patients who are likely to experi-
ence deterioration of renal function in the future.
With respect to the relationship between urinary L-FABP and
DN, increased urinary L-FABP is widely known to be associated with
the severity of DN [11–15] and the progression of DN in future
[11,14,16,17]. Furthermore, there have been numerous reports of in-
tervention studies in which urinary L-FABP possesses response to
renoprotective treatment [12,13,18–24]. This review summarizes re-
cent ﬁndings on the clinical signiﬁcance of urinary L-FABP in DN.
Those ﬁndings showed that urinary L-FABP concentrations increased
in parallel with the progression of DN and that high concentrations
of urinary L-FABP presented a risk of progression of DN, of cardiovas-
cular events and anemia.
2. Measurements of urinary L-FABP
To avoid variations that occur through differences in the ELISA kit
used for measuring urinary L-FABP concentrations, only studies
pertaining to the clinical signiﬁcance of urinary L-FABP measured
using the Human L-FABP ELISA Kit developed by CMIC Co., Ltd.
(Tokyo, Japan)were reviewed [10]. In 2010, theMinistry of Health, La-
bour and Welfare approved the use of only this kit for diagnosis in
clinical practice in Japan. The urinary L-FABP concentration was
expressed as the ratio of the urinary L-FABP concentration to the uri-
nary creatinine concentration in all studies.
To determine control reference values for urinary L-FABP in spot
urine, 412 healthy volunteers were examined [11]. The mean value
of urinary L-FABP in spot urine, determined from the logarithmic-
transformed data (log L-FABP), was 1.6 μg/g creatinine, with individual
values ranging from 0.3 μg/g creatinine (mean − 2 SD) to 8.4 μg/g
creatinine (mean + 2 SD).
3. Dynamics of renal L-FABP in DN from an experimental study
Because renal L-FABP is not endogenously expressed in the kidneys
of mice, we generated human L-FABP chromosomal transgenic (Tg)
mice and evaluated the dynamics and pathophysiological role of renal
L-FABP [25].With regard to DN, a streptozotocin (STZ)-induced diabetic
model, which has type 1 diabetes, was used and tubulointerstitial dam-
age was provoked [6]. Our ﬁndings revealed that renal human L-FABP
gene expression was up-regulated (around 9-fold increase) and that
urinary excretion of human L-FABP increased (around 9-fold increase)
in the STZ-induced diabetic Tg mice compared with control mice at
8 weeks after STZ injection. From the observation of lipid accumulation
in human proximal tubules inDN [26], it could be suggested that lipid or
peroxidation product generated in the proximal tubules of DN might
promote the up-regulation of renal L-FABP expression. Our Tg mice
were generated by microinjections of the genomic DNA of human
L-FABP including its promoter region; therefore, it is possible for the
transcription of the human L-FABP gene in the Tg mice to be regulated
in the same mode as in humans. The dynamics of human L-FABP in
the experimental diabetic model mightmimic those under pathological
conditions in humans as reported in the clinical cross-sectional studies
described below.4. Clinical signiﬁcance of urinary L-FABP in diabetic nephropathy
4.1. Cross-sectional studies (Table 1)
Two studies of type 1 diabetes [13,14] and three studies of type 2 di-
abetes [11,12,15] reported on the relationship between urinary L-FABP
concentrations and the severity of DN. In type 1 diabetes, urinary
L-FABP concentrations increased with the progression of DN and were
higher in normoalbuminuric patients than in control subjects [13,14].
These results indicated that urinary L-FABP accurately reﬂected DN se-
verity and may be a suitable biomarker for early detection of DN.
Why urinary L-FABP concentrations increased in patients with
normoalbuminuria in comparison with control subjects is not yet
known. It is possible that in the normoalbuminuric phase chronic
hyperglycemia may provoke microvascular damage [27], leading to
tubular hypoxia and ﬁnally tubulointerstitial damage. Tubular hypoxia
activates hypoxia inducible factor-1 (HIF-1) [28], which binds the hyp-
oxia responsive element in the promoter region of the L-FABP gene,
up-regulates the gene expression of L-FABP and promotes urinary ex-
cretion of L-FABP [4]. Therefore, chronic hypoxia could have induced
an increase in urinary L-FABP in the normoalbuminuric phase.
In type 2 diabetes, urinary L-FABP concentrations increased with the
progression of DN [11,12,15] and reﬂected DN severity. In one report,
urinary L-FABP levels were signiﬁcantly higher in patients with
normoalbuminuria than in control subjects [11]. However, among clini-
cal studies of type 2 diabetes, urinary L-FABP concentrations were com-
parable between patients with normoalbuminuria and those with
microalbuminuria [15] and between patients with normoalbuminuria
and control subjects [12]. In the study of Suzuki et al. [15], the frequency
of measuring urinary albuminwas not described and the urinary L-FABP
concentration in patients with microalbuminuria (mean value, 5.2 μg/g
creatinine [15]) was lower than that reported in other studies (mean
value, 8.6 μg/g creatinine [11] or 19.6 μg/g creatinine [12]). Possibly
the frequency of urinary albumin measurements was insufﬁcient and
the diagnosis of DN severity according to the urinary albumin concentra-
tion led to over-diagnosis. Therefore, patients with normoalbuminuria
might have been entered by mistake into the microalbuminuria group,
resulting in a lower median or average urinary L-FABP concentration in
themicroalbuminuria group. In the study of Nakamura et al. [12], urinary
L-FABP in the control subjects (mean value, 5.8 μg/g creatinine) was
higher than that reported in another study (mean value, 1.6 μg/g creati-
nine [11]) andwas almost the same as that ofmicroalbuminuric patients
in another study (mean value, 5.2 μg/g creatinine [15]). It is possible that
the criteria for the selection of control subjects was not sufﬁciently strict
and that the number of control subjects was too small [12]. Because DN
developing from type 2 diabetes is known to be amultifactorial disorder
that can deteriorate through the presence of various factors such as hy-
perglycemia, hypertension, obesity and hyperlipidemia and since type
2 diabetes patients are more heterogeneous than type 1 diabetes pa-
tients, identical results might not be obtainable in clinical studies of
type 2 diabetes. Furthermore, cut-off values for urinary L-FABP for detec-
tion of normo- or microalbuminuria have not been investigated yet.
These points should be considered in future clinical studies.
Anemia induces tubular hypoxia and leads to the progression of DN
[29,30], and is frequently observed even in diabetic patients in the early
stage of DN. These patients not only experience a fast decline in renal
function, but also increased mortality and morbidity [31,32]. The corre-
lation between urinary L-FABP and anemia has been studied [33]. The
superiority of urinary L-FABP in comparison with urinary kidney injury
molecule (KIM-1) [34] and urinary N-acetyl-b-glucosaminidase (NAG),
known as another tubular damage marker, was emphasized. That re-
search involved 130 type 2 diabetes patients with albuminuria and cre-
atinine clearancemore than 60 mL/min and 40 healthy control subjects
[33]. Only urinary L-FABP was correlated with the hematocrit (r =
−0.188, p = 0.032), hemoglobin (r = −0.190, p = 0.030) and ane-
mia based on the WHO deﬁnition (r = −0.266, p = 0.002), but not
Table 1
Characteristics of cross sectional studies of diabetic nephropathy (DN).
Type of diabetes No. subjects
Control/DM
Deﬁnition of DN severity (No. stages) Kind of urine sample Change in urinary L-FABP level Year, Ref No.
Relationship between urinary L-FABP and DN severity
Type 1 diabetes 57/148 Levels of urinary albumin determined in
3 consecutive 24-h urine samples (3 stages)
First morning urine Normoalbuminuria group > *Control group.
Increase with increase in urinary albumin levels.
2009, 13
208/2454 Levels of urinary albumin determined in
3 consecutive 24-h urine samples (3 stages)
24-h urine Normoalbuminuria group > *Control group.
Increase with increase in urinary albumin levels.
2013, 14
Type 2 diabetes 0/356 Levels of urinary albumin determined in ﬁrst
morning urine and serum creatinine (4 stages)
First- morning urine Increase with increase in urinary albumin levels
and with renal dysfunction.
Normoalbuminuria microalbuminuria.
Comparison with control group not reported.
2005, 15
20/58 Levels of urinary albumin determined in 24-h
urine and serum creatinine samples (4 stages)
24-h urine Normoalbuminuria group Control group.
Increase with increase in urinary albumin levels
and with renal dysfunction.
2005, 12
412/140 Levels of urinary albuminuria determined in
3 consecutive spot urine and serum creatinine
samples (4 stages)
Spot urine Normoalbuminuria group > *Control group.
Increase with increase in urinary albumin levels
and with renal dysfunction.
2011, 11
Relationship between urinary L-FABP and anemia
Type 2 diabetes 40/130 Levels of urinary albumin and creatinine clearance
determined in 3 consecutive 24-h urine samples.
24-h urine Close relation between urinary L-FABP levels
and chronic anemia.
2010 33
Ref, Reference. >*, signiﬁcantly higher (p b 0.05).
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(n = 30) had signiﬁcantly higher urinary L-FABP than non-anemic dia-
betes patients (n = 100). In groups formed according to tertiles of in-
creasing urinary L-FABP concentrations, a stepwise increase in urinary
L-FABP was associated with decreasing hemoglobin levels. Further-
more, in multivariable adjusted logistic regression analysis to identify
independent factors for the increasing urinary L-FABP concentrations,
anemia (odds ratio, 6.06; 95% CI: 1.652–22.232; p = 0.039) was a sig-
niﬁcant risk factor for increased urinary L-FABP excretion. The authors
concluded that urinary L-FABP was a highly sensitive marker of a
renal microcirculation disorder induced by anemia, which is a factor
in the progression of DN. Two other studies support this conclusion;
one reported that in patients with chronic renal failure, administration
of erythropoietin decreased urinary L-FABP along with an increase
in hemoglobin [35], and the other showed that in kidney transplant
recipients, urinary L-FABP concentrations increased in parallel with de-
creased peritubular capillary blood ﬂow, which was shown using
non-invasive CCD video recording [4].
Although the mechanism by which anemia increased urinary
L-FABP excretion was not revealed [33], it was speculated that tubular
hypoxia induced by anemia up-regulates the gene expression of
L-FABP and promotes the urinary excretion of L-FABP. In future, when
new treatments for kidney disease that improve tubular hypoxia are de-
veloped, urinary L-FABPwill be a useful target for therapeutic regimens.
4.2. Prospective observational follow-up studies (Table 2)
Of prospective observational studies of patients with diabetes, three
studies of type 1 diabetes [14,17,36] and two studies of type 2 diabetes
[11,16] were performed. In type 1 diabetes, Cox regression analysis in-
dicated that urinary L-FABP was an independent predictor of progres-
sion from normoalbuminuria in two studies [14,17] and in one study
of the progression to macroalbuminuria over a period of more than
6 years [14]. Inmicroalbuminuric patients with type 1 diabetes, univar-
iate analysis (odds ratio, 1.49; 95% CI: 1.20–1.85, p b 0.001) and multi-
variate analysiswithout urinary albumin (odds ratio, 1.40; 95% CI: 1.10–
1.79, p = 0.006) showed that L-FABP was a predictor of progression to
microalbuminuria [14]. However, when urinary albuminwas added as a
variable in Cox regression analysis, an increase in urinary L-FABP was
not associated with a higher risk of progression to microalbuminuria
(odds ratio, 0.67; 95%: CI 0.48–0.95, p = 0.027) [14]. One possibility
for this result is that the urinary L-FABP concentrations were strongly
correlated with the urinary albumin concentrations and that each of
these two parameters became a confounding factor in Cox regressionanalysis. Regarding the merit of measuring urinary L-FABP in addition
to urinary albumin in type 1 diabetes, the area under the receiver oper-
ating characteristic curve (AUC) for predicting the progression of DN at
each stage of DNwas studied [14]. Although predicting the progression
tomacroalbuminuria or end stage renal failure using urinary L-FABP to-
getherwith urinary albumin appears to haveno clinical beneﬁt, theAUC
when using both urinary L-FABP and urinary albumin (AUC = 0.786)
to predict the progression to microalbuminuria was higher than with
urinary albumin alone (AUC = 0.778, p = 0.092) in patients with
normoalbuminuria. Taken together, in type 1 diabetes, urinary L-FABP
may be a useful biomarker for predicting progression from the earliest
stage of DN and there may be an advantage in measuring urinary
L-FABP in addition to urinary albumin.
In one study in which the correlation between urinary L-FABP and
a decline in the glomerular ﬁltration rate (GFR) in type 1 diabetes pa-
tients with macroalbuminuria was evaluated for a short duration
(3 years), urinary L-FABP was not predictive of a decline in GFR
[36]. An observational study with a longer follow-up period is needed
to clarify this point.
The two studies of this issue in type 2 diabetes were performed in
Japan [11,16]. One study showed that urinary L-FABPwas an indepen-
dent predictor of progression of DN, which was deﬁned as advance-
ment to the next higher stage in patients with all stages of DN
without the requirement of dialysis or kidney transplantation; analy-
sis of a subgroup with an estimated GFR (eGFR) >60 ml/min per
1.73 m2 showed results consistent with the former result [11]. A
high urinary L-FABP value at study entry (than upper limit of refer-
ence value of urinary L-FABP, 8.4 μg/g creatinine) was a higher risk
factor for progression of DN than the presence of albuminuria at
entry [11]. Although without signiﬁcance (p = 0.45), the AUC for
predicting the progression of DN by urinary L-FABP (AUC = 0.762)
was higher than that by urinary albumin (AUC = 0.675) in the sub-
group with an eGFR >60 ml/min per 1.73 m2 [11]. Furthermore,
when the primary endpoint was deﬁned as the requirement for dial-
ysis or a cardiovascular event in patients with normoalbuminuria or
microalbuminuria, the incidence rate of the primary endpoint in-
creased in a stepwise manner with increases in urinary L-FABP by
Cox regression analysis (odds ratio, 2.16; 95% CI: 1.23–3.79) [16].
Although urinary L-FABP also may be an appropriate biomarker for
predicting progression from the earliest stage of DN or to cardiovas-
cular events in type 2 diabetes, there have been few studies from
Japan and none elsewhere on this topic. Further studies are needed
to reconﬁrm the potential of urinary L-FABP as a predictor of the pro-
gression of DN or of cardiovascular events.
Table 2
Characteristics of prospective observational follow-up studies of diabetic nephropathy (DN).
Type of diabetes No. subjects
(follow-up
periods: year)
Primary endpoints Baseline of DN severity Cox regression analysis using
progression of DN, Adjusted
odds ratio (95%CI)
Year, Ref No.
Type 1 diabetes 165 (18) Increase in urinary albumin levels
determined in 24-h urine sample
Normo-albuminuria 2.28 (1.14–4.58) 2010, 17
356 (6–10) Increase in urinary albumin levels
determined in 24-h urine and
requirement of dialysis or kidney
transplantation
All stages of DN without
requirement of dialysis
or kidney transplantation
Progression from normoalbuminuria
2.97 (1.50–5.90)
Progression from microalbuminuria
0.67(0.48–0.95)
Progression from macroalbuminuria
1.17 (1.10–1.24)
2013, 14
63 (3) Decline in GFR measured as plasma
clearance of an intravenous
injection of 51Cr-EDTA.
Macroalbuminuria with GFR
>60 ml/min per 1.73 m2
Not reported.
Not predictive of decline in GFR.
All patients 7.29 (2.43–21.88)
2011, 36
Type 2 diabetes 104 (4) Increase in urinary albumin levels
determined in 3 consecutive spot
urine and serum creatinine samples
All stages of DN without
requirement of dialysis
or kidney transplantation
Patients with eGFR >60 mL/min
per 1.73 m2
9.46 (2.24–39.92)
2011, 11
618 (11–15) Requirement of dialysis or
cardiovascular events
Normo- and microalbuminuria
with serum creatinine b1.0 mg/dL
2.16 (1.23–3.79) 2013, 16
Ref, Reference; GFR, glomerular ﬁltration rate; eGFR, estimated GFR.
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Two studies of type 1 diabetes reported changes in urinary L-FABP
by intervention with angiotensin converting enzyme inhibitor
(ACE-I) [13] or aldosterone blockade [24]. Using ACE-1 [13] or aldo-
sterone blockade [24], urinary L-FABP concentrations decreased [13]
or tended to decrease [24] along with decreases in urinary albumin
concentrations. In type 2 diabetes, two studies using a statin [12,18],Table 3
Characteristics of intervention studies of diabetic nephropathy (DN).
Type of
diabetes
No. subjects
(intervention
periods: months)
Content of treatment
(generic name, dose/day)
Pr
Type 1 diabetes 48 (8) ACE-I (lisinopril, 20 mg,
40 mg, 60 mg)
C
21 (2) Aldosterone blockade
(spironolactone, 25 mg)
C
Type 2 diabetes 20 (12) Statin (pitavastatin, 1 mg) C
104 (6) Statin (rosuvastatin, 2.5 mg) C
eG
u
68 (12) Antidiabetes drugs (pioglitazone
30 mg, glibenclamide 5 mg, voglibose
0.6 mg, nateglinide, 270 mg)
C
45 (12) Calcium channel blocker
(azelnidipine, 8 mg, 16 mg)
C
67 (6) Calcium channel blocker
(azelnidipine, 8 mg, 1 6 mg,
amlodipine, 2.5 mg, 5 mg)
C
se
68 (12) ARB (losartan, 100 mg, candesartan,
12 mg, olmesartan, 40 mg,
telmisartan, 80 mg)
C
an
64 (6) Renin inhibitor (aliskiren, 150 mg, 300 mg,)
Calcium channel blocker
(amlodipine, 5 mg, 7.5 mg)
C
eG
Ref, Reference; ACE-I; angiotensin converting enzyme inhibitor; ARB; angiotensin II receptoone using antidiabetes drugs [23], two using a calcium channel
blocker [19,22], one using a blocker of the renin-angiotensin system
[20,21], and one using a blocker of the renin-angiotensin system
and a calcium channel blocker [20] were reported from Japan. Results
showed that urinary L-FABP decreased through the use of various
renoprotective interventions and that urinary L-FABP had a drug re-
sponse. Urinary L-FABP may be useful as a surrogate marker for the
effectiveness of therapy.imary endpoints Changes in urinary L-FABP Year,
Ref No.
hanges in urinary albumin. Reduction in urinary L-FABP was
associated with changes in urinary
albumin, but not with dose of lisinopril.
2009, 13
hanges in urinary albumin. Urinary L-FABP levels tended to decrease
after spironolactone treatment along
with reduction of urinary albumin.
2012, 24
hanges in urinary albumin. Urinary L-FABP levels decreased after
pitavastatin treatment along with
reduction of urinary albumin.
2005, 12
hanges in serum creatinine,
FR, serum cystatin C and
rinary albumin.
Urinary L-FABP levels decreased
after rosuvastatin treatment along
with reduction of urinary albumin.
Although serum creatinine and eGFR
did not signiﬁcantly decrease, serum
cystatin C levels signiﬁcantly decreased.
2011, 18
hanges in urinary albumin. Urinary L-FABP levels decreased after
pioglitazone treatment along with
reduction in urinary albumin.
2006, 23
hanges in urinary albumin. Urinary L-FABP levels decreased after
azelnidipine treatment dose-dependently
along with reduction in urinary albumin.
2008, 22
hanges in urinary albumin,
rum creatinine and eGFR.
Urinary L-FABP levels decreased after
azelnidipine treatment along with
reduction in urinary albumin.
Serum creatinine and eGFR did not
signiﬁcantly decrease.
2011, 19
hanges in urinary albumin
d 24-h Ccr.
Urinary L-FABP levels decreased after
ARB treatment along with reduction in
urinary albumin.
Ccr did not decrease.
2010, 21
hanges in serum creatinine,
FR, and urinary albumin.
Urinary L-FABP levels decreased after
aliskiren or amlodipine treatments along
with reduction in urinary albumin.
serum creatinine and eGFR did not
signiﬁcantly decrease.
2012, 20
r blocker; Ccr; creatinine clearance; eGFR; estimated glomerular ﬁltration rate.
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Although studies in which the advantages of urinary L-FABP com-
pared to the existing clinical markers have been few [11,14], the clinical
relevance of urinary L-FABP as a predictor of progression of DN
[11,14,17], of requirement for dialysis or cardiovascular events [16] and
of anemia [33], or as a target for therapeutic regimens [12,13,18–24]
was demonstrated by some clinical studies. However, tubular markers,
including urinary L-FABP, did not predict a decline in GFR in patients
with DN with overt nephropathy in one study [36]. Furthermore,
because the progression of DN was deﬁned as an increase in urinary
albumin concentrations until progression to end stage renal failure, it
may be difﬁcult to determine that the potency of urinary L-FABP for di-
agnosis or prediction of progression of DN is higher than that of urinary
albumin. Therefore, further large multicenter clinical studies on large
populations are expected to be performed in future to reconﬁrm the clin-
ical usefulness of urinary L-FABP on another important endpoint apart
from an increase in the urinary albumin level, such as prediction of the
need for dialysis, cardiovascular events and death in each stage of DN
severity.
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